Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Agmatine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.54 |
| ▸ | F3 | P13726 | 1/20 | 0.54 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.54 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.54 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.54 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.54 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Spermidine SCHEMBL25434620 | 0.82 | F7 (0.63) | F7F3SARM1SIRT2SIRT6 | |
| Hydrochloric Acid SCHEMBL27838038 | 0.81 | EPHX2 (0.61) | EPHX2KEAP1NFE2L2CYP3A4RAB9A | |
| Niacinamide SCHEMBL6710701 | 0.80 | F7 (0.85) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL10897800 | 0.79 | EPHX2 (0.66) | EPHX2ABL1BCRKEAP1NFE2L2 | |
| SCHEMBL15923129 | 0.78 | EPHX2 (0.64) | EPHX2ABL1BCRKEAP1NFE2L2 | |
| SCHEMBL22170882 | 0.78 | EPHX2 (0.64) | EPHX2ABL1BCRKEAP1NFE2L2 | |
| Niacinamide SCHEMBL3691699 | 0.77 | F7 (0.79) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL30754072 | 0.77 | F7 (0.79) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL2881504 | 0.77 | F7 (0.79) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL5712651 | 0.77 | F7 (0.85) | F7F3SARM1SIRT2SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128593-A1 | SYNERGISTIC NUTRITIONAL NEUROPROTECTIVE COMPOSITIONS FOR AMELIORATING NEURAL DYSFUNCTION | Celagenex Research (India) Pvt. Ltd. (IN) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128593-A1 | SYNERGISTIC NUTRITIONAL NEUROPROTECTIVE COMPOSITIONS FOR AMELIORATING NEURAL DYSFUNCTION | NNMT, RIMKLA, NLN | F7 4617/4885F3 3776/4885SARM1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.